The Metabolic Institute of America | Strategic Alliance Partnership

In a panel at the 5th annual Heart in Diabetes Conference, John McMurray, MD, and Javed Butler, MD, highlighted recent pharmacological developments in heart failure (HF) and offered insights on overlooked areas in the field.

A session at the 5th annual Heart in Diabetes Conference highlights the long-term risks of gestational diabetes.

New research presented at the 5th Heart in Diabetes Conference highlights potential therapeutic options for patients with COVID-19 and diabetes.

In a session at the 18th annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease presented by the Metabolic Institute of America, experts discussed challenges faced by patients with diabetes in the wake of the coronavirus disease 2019 (COVID-19) pandemic and lessons learned from the crisis.

One of the best ways to increase compliance when treating diabetes is to ensure patients fully understand the importance of treatment, according to Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America. However, this can be difficult for physicians with a limited amount of time for patient visits.

Recent advances in insulin formulations and innovative drug classes have made it easier than ever to manage diabetic patients’ glucose levels, according to Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.